Junshi grants exclusive rights to Dr. Reddy's for toripalimab cancer treatment
Client(s) Shanghai Junshi Biosciences Co., Ltd.
Jones Day represented Shanghai Junshi Biosciences Co., Ltd. ("Junshi") in its grant of exclusive rights related to the development and commercialization of toripalimab, an anti-PD1 monoclonal antibody, to Dr. Reddy's Laboratories for the territory of Latin America, India, South Africa, and an option to expand the territory to include Australia and New Zealand and potential other countries. Junshi also granted rights of first negotiation with respect to two additional products for the same geographical regions. Toripalimab is in various states of clinical trials throughout the world evaluating the safety and efficacy for the treatment of cancer tumors of the lungs, esophagus, stomach, bladder, breast, liver, kidney, and skin, and has been approved in China and marketed under the TUOYI® trademark.